Regulatory Sub-Classification of Phase I Studies: `Phase 0.5' ?

ISSN： 1364-9027

Source： International Journal of Pharmaceutical Medicine, Vol.19, Iss.1, 2005-01, pp. : 3-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What can be done to improve patient safety in phase I trials?

Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

A Role for Two-Stage Pharmacoeconomic Appraisal?: Is There a Role for Interim Approval of a Drug for Reimbursement Based on Modelling Studies with Subsequent Full Approval Using Phase III Data?

By Hill S.

PharmacoEconomics, Vol. 21, Iss. 11, 2003-01 ,pp. : 761-767

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic evaluations alongside phase III trials?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 424, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Economic Evaluations During Early (Phase II) Drug Development: A Role for Clinical Trial Simulations?

By Hughes D.A. Walley T.

PharmacoEconomics, Vol. 19, Iss. 11, 2001-11 ,pp. : 1069-1077

Adis International

Access to resources Recommend Favorite

Regulatory Affairs Revisited: Practitioner or Professional?

By Gundersen L.E.

International Journal of Pharmaceutical Medicine, Vol. 17, Iss. 3-4, 2003-01 ,pp. : 117-122

Adis International

Access to resources Recommend Favorite